As many drugmakers scale down their R&D presences in India, Bristol-Myers Squibb is strengthening its relationship with Syngene, the CRO arm of local giant Biocon.
CRO Parexel International has been working to better unify its disparate service divisions, and now the company has named its first chief scientific officer to oversee its end-to-end offerings.
In the midst of an ongoing reorganization, contract developer AMRI has made another buy in manufacturing, signing a deal to scoop up CMO OsoBio for $110 million in cash.
WuXi PharmaTech has increased its manufacturing capabilities in China, bolstering its fastest-growing business as it looks to expand around the globe.
Global CRO INC Research has teamed up with a trade group of clinical research sites, lending its expertise in an effort to better integrate sponsors, CROs and investigators in the R&D process.
German researcher Evotec has signed a deal to pay as much as $5.3 million for specialty CRO Euprotec, a company focused on anti-infective drug discovery.
Vaccine developer Advaxis is teaming up with CRO inVentiv Health to advance a stable of oncology candidates that work by mounting an immune system attack on cancer tissue.
Clinical trial software provider Clinverse has inked a deal with eClinical Insights to share resources and unite their technologies.
U.K. outsourcers PolyTherics and Antitope have merged to pool their R&D resources, christening the combined company Abzena and targeting the bustling biomedical hub of Cambridge for new headquarters.
Rho, a midsize contract researcher out of North Carolina, is looking to expand its footprint to deal with a widening client base, setting out to expand its ranks of investigators and execs.
Cloud-based data magnate Medidata has signed a deal with TransCelerate BioPharma, a consortium of the world's largest drugmakers, to modernize the way the industry conducts clinical trials.
As the industry embraces risk-based clinical trial monitoring, Parexel International is expanding its banner eClinical offering to help sponsors make data-driven decisions in the middle of a study.
Global CRO Covance is looking to expand its share of the drug-commercialization space, buying up a U.K. market access specialist to help its clients sell their approved products.
China's WuXi PharmaTech has completed work on a biologics safety testing facility in Suzhou, adding 38,000 square feet of lab space to its sprawling presence in the area.
Bayer is joining the bandwagon of drugmakers getting in on clinical trial transparency, signing on to share some of its data with researchers but stopping well short of industry trailblazers.
Oft-merged CRO giant PRA has expanded its large-molecule capabilities in the U.S., setting up a bioanalysis shop right next to its clinics to make for faster trials.
Germany's Evotec splits its operation between contract research for big-name third parties and in-house work on its own pipeline, riding its uncommon take on the CRO business to an uptick in revenue last quarter.
Chinese CRO WuXi PharmaTech notched another strong sales quarter, boosting its revenue by 11.3% thanks to escalating demand for its manufacturing services.
Quintiles, the world's largest CRO, is further expanding its outside-the-clinic business, agreeing to buy healthcare analytics outfit Encore Health Resources to beef up its access to real-world patient data.
Irish CRO Icon has closed out its $143.5 million acquisition of Aptiv Solutions, a deal designed to amp up its technology and expand its presence in Japan.